Expression of G protein-coupled receptor kinase 4 is associated with breast cancer tumourigenesis

Journal of Pathology

Volumn 216, Issue 3, 2008, Pages 317-327

  Matsubayashi, J ^a   Takanashi, M ^a   Oikawa, K ^a   Fujita, K ^a   Tanaka, M ^a   Xu, M ^a   De Blasi, A ^b   Bouvier, M ^c   Kinoshita, M ^d   Kuroda, M ^a   Mukai, K ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d National Hospital Organization   (Japan)

Author keywords

arrestin; Breast cancer; GPCR; GRK4; MAPK

Indexed keywords

BETA ARRESTIN; G PROTEIN COUPLED RECEPTOR KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ARRESTINS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 4; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 55249127104     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2414     Document Type: Article

References (43)

1. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993;85:892-897.
2. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over-expressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
3. Ro J, North SM, Gallick GE, Hortobagyi GN, Gutterman JU, Blick M. Amplified and over-expressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res 1988;48:161-164.
4. Spyratos F, Delarue JC, Andrieu C, Lidereau R, Champeme MH, Hacene K, et al. Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 1990;17:83-89.
5. Krupnick JG, Benovic JL. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 1998;38:289-319.
6. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem 1998;67:653-692.
7. Penela P, Ribas C, Mayor F Jr. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal 2003;15:973-981.
8. Somers RL, Klein DC. Rhodopsin kinase activity in the mammalian pineal gland and other tissues. Science 1984;226:182-184.
9. Hisatomi O, Matsuda S, Satoh T, Kotaka S, Imanishi Y, Tokunaga F. A novel subtype of G-protein-coupled receptor kinase, GRK7, in teleost cone photoreceptors. FEBS Lett 1998;424:159-164.
10. Weiss ER, Raman D, Shirakawa S, Ducceschi MH, Bertram PT, Wong F, et al. The cloning of GRK7, a candidate cone opsin kinase, from cone- and rod-dominant mammalian retinas. Mol Vis 1998;4:27.
11. Sallese M, Mariggio S, Collodel G, Moretti E, Piomboni P, Baccetti B, et al. G protein-coupled receptor kinase GRK4. Molecular analysis of the four isoforms and ultrastructural localization in spermatozoa and germinal cells. J Biol Chem 1997;272:10188-10195.
12. Virlon B, Firsov D, Cheval L, Reiter E, Troispoux C, Guillou F, et al. Rat G protein-coupled receptor kinase GRK4: identification, functional expression, and differential tissue distribution of two splice variants. Endocrinology 1998;139:2784-2795.
13. Sallese M, Salvatore L, D'Urbano E, Sala G, Storto M, Launey T, et al. The G-protein-coupled receptor kinase GRK4 mediates homologous desensitization of metabotropic glutamate receptor 1. FASEB J 2000;14:2569-2580.
14. Pi M, Oakley RH, Gesty-Palmer D, Cruickshank RD, Spurney RF, Luttrell LM, et al. β-Arrestin- and G protein receptor kinase-mediated calcium-sensing receptor desensitization. Mol Endocrinol 2005;19:1078-1087.
15. Kuhn H. Light-regulated binding of rhodopsin kinase and other proteins to cattle photoreceptor membranes. Biochemistry 1978;17:4389-4395.
16. Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, et al. β-Arrestin 2, a novel member of the arrestin/β-arrestin gene family. J Biol Chem 1992;267:17882-17890.
17. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by β-arrestins. Science 2005;308:512-517.
18. Oikawa K, Ohbayashi T, Kiyono T, Nishi H, Isaka K, Umezawa A, et al. Expression of a novel human gene, human wings apart-like (hWAPL), is associated with cervical carcinogenesis and tumor progression. Cancer Res 2004;64:3545-3549.
19. Perroy J, Adam L, Qanbar R, Chenier S, Bouvier M. Phosphorylation- independent desensitization of GABA(B) receptor by GRK4. EMBO J 2003;22:3816-3824.
20. Premont RT, Macrae AD, Stoffel RH, Chung N, Pitcher JA, Ambrose C, et al. Characterization of the G protein-coupled receptor kinase GRK4. Identification of four splice variants. J Biol Chem 1996;271:6403- 6410.
21. Premont RT, Macrae AD, Aparicio SA, Kendall HE, Welch JE, Lefkowitz RJ. The GRK4 subfamily of G protein-coupled receptor kinases. Alternative splicing, gene organization, and sequence conservation. J Biol Chem 1999;274:29381-29389.
22. Rankin ML, Marinec PS, Cabrera DM, Wang Z, Jose PA, Sibley DR. The D1 dopamine receptor is constitutively phosphorylated by G protein-coupled receptor kinase 4. Mol Pharmacol 2006;69:759-769.
23. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-1494.
24. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-2446.
25. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
26. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol Endocrinol 2001;15:1344-1359.
27. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, et al. Re-expression of estrogen receptor α in estrogen receptor α-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signalling and growth. Cancer Res 2001;61:5771- 5777.
28. Miller WE, Lefkowitz RJ. Expanding roles for β-arrestins as scaffolds and adapters in GPCR signalling and trafficking. Curr Opin Cell Biol 2001;13:139-145.
29. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, et al. β-Arrestin-dependent formation of β2-adrenergic receptor-Src protein kinase complexes. Science 1999;283:655-661.
30. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, et al. β-Arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 2000;290:1574-1577.
31. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW. β-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 2000;148:1267-1281.
32. Kim J, Ahn S, Ren XR, Whalen EJ, Reiter E, Wei H, et al. Functional antagonism of different G protein-coupled receptor kinases for β-arrestin-mediated angiotensin II receptor signalling. Proc Natl Acad Sci USA 2005;102:1442-1447.
33. Willets JM, Challiss RA, Nahorski SR. Non-visual GRKs: are we seeing the whole picture? Trends Pharmacol Sci 2003;24:626-633.
34. Zeng C, Sanada H, Watanabe H, Eisner GM, Felder RA, Jose PA. Functional genomics of the dopaminergic system in hypertension. Physiol Genomics 2004;19:233-246.
35. Premont RT, Inglese J, Lefkowitz RJ. Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J 1995;9:175-182.
36. 2+/calmodulin. J Biol Chem 1996;271:28691-28696.
37. Wilson CJ, Applebury ML. Arresting G-protein coupled receptor activity. Curr Biol 1993;3:683-686.
38. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, et al. Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc Natl Acad Sci USA 2001;98:2449- 2454.
39. DeFea KA, Vaughn ZD, O'Bryan EM, Nishijima D, Dery O, Bunnett NW. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 2000;97:11086-11091.
40. Nobles KN, Guan Z, Xiao K, Oas TG, Lefkowitz RJ. The active conformation of β-arrestin 1: direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of β-arrestins 1 and 2. J Biol Chem 2007;282:21370-21381.
41. Wang P, Gao H, Ni Y, Wang B, Wu Y, Ji L, et al. β-Arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2. J Biol Chem 2003;278:6363-6370.
42. Yang JY, Zong CS, Xia W, Wei Y, Ali-Seyed M, Li Z, et al. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol 2006;26:7269-7282.
43. Wilson S, Bergsma DJ, Chambers JK, Muir AI, Fantom KG, Ellis C, et al. Orphan G-protein-coupled receptors: the next generation of drug targets? Br J Pharmacol 1998;125:1387-1392.